A5061388899- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cytokine Signaling Pathways and Interactions
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- IL-33, ST2, and ILC Pathways
- Prostate Cancer Treatment and Research
- Immune cells in cancer
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Ferroptosis and cancer prognosis
- Cancer-related cognitive impairment studies
- S100 Proteins and Annexins
- Vitamin D Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Bone health and treatments
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- Nausea and vomiting management
- Chemotherapy-induced cardiotoxicity and mitigation
Center for Cancer and Blood Disorders
2013-2024
Sheffield Teaching Hospitals NHS Foundation Trust
2020
Weston Park Cancer Centre
2020
Henry Ford Health System
2017
Sarah Cannon Research Institute
2017
Texas Oncology
2017
Heidelberg University
2017
University Hospital Heidelberg
2017
Sarah Cannon
2017
Hematology Oncology Consultants
2015
Primary analyses of the phase III BrighTNess trial showed addition carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from trial.Women untreated stage II-III TNBC were randomized (2 : 1 1) paclitaxel (weekly for 12 doses) plus: (i) (every 3 weeks four cycles) plus (twice daily); (ii) placebo; or...
Abstract Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1β in primary breast cancer tumors is linked with advanced disease originates from tumor-infiltrating CD11c+ myeloid cells. triggered by cell membrane–derived TGFβ. Neutralizing TGFβ or IL1 receptor prevents progression humanized mouse model. Patients metastatic HER2− display a transcriptional signature inflammation the blood leukocytes, which attenuated after blockade. When...
BackgroundMetastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), gemcitabine (nab-P/G), (G/C) in patients with mTNBC.Patients methodsPatients pathologically confirmed mTNBC no prior chemotherapy for metastatic BC received (1 : 1 1) nab-P 125 mg/m2 C AUC 2, G 1000 mg/m2, or all on days 1, 8 q3w. Phase II primary end point: investigator-assessed...
Abstract BACKGROUND: The randomized, controlled BOLERO‐2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression‐free survival with the use everolimus plus exemestane (EVE + EXE) versus placebo (PBO in patients advanced breast cancer who developed disease progression after treatment nonsteroidal aromatase inhibitors. This analysis investigated effects on health‐related quality life (HRQOL). METHODS: Using European Organisation for Research and...
Abstract Background: Trastuzumab deruxtecan (T-DXd) is approved in over 40 countries for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (a score 1+ on immunohistochemistry [IHC] analysis an IHC 2+ and negative results in-situ hybridization) breast cancer who have received prior chemotherapy setting developed disease recurrence during within 6 months completing adjuvant chemotherapy. DESTINY-Breast08 (DB-08) was designed to...
4609 Background: Ipilimumab is a fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 and augments immune responses. The current study evaluated the safety activity of ipilimumab alone or with single dose docetaxel in hormone-refractory prostate cancer (HRPC). Methods: 43 chemotherapy naïve patients (pts) HRPC, were treated; 23 arm A (ipilimumab at 3 mg/kg q 4 weeks × doses) 20 B as Arm one 75 mg/m 2 on day 1). Results: Six pts, each arm, demonstrated decrease PSA > 50%....
Abstract Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor 2-positive (HER2+) breast cancers. In vitro , AR inhibitors enhance antitumor activity trastuzumab, an anti-HER2 antibody, trastuzumab-resistant HER2+ cell lines. This open-label, single-arm, phase II study evaluated the efficacy and safety enzalutamide, AR-signaling inhibitor, patients with advanced AR+ cancer previously treated trastuzumab. Methods Eligible had measurable or...
Abstract Background: nab-Paclitaxel (nab-P)–containing regimens have demonstrated efficacy and safety in triple-negative breast cancer (TNBC). In the absence of a standard care for metastatic (m) TNBC, tnAcity evaluated 3 common chemotherapy combination regimens: nab-P + carboplatin (nab-P/C) or gemcitabine (nab-P/G) vs G/C as first-line treatment (Tx) patients (pts) with mTNBC based on ranking algorithm safety. Results phase 2 portion are reported here. Methods: Pts pathologically confirmed...
e14565 Background: Higher intratumoral IL-1b levels correspond with advanced stages of MBC. We hypothesized that anakinra (Ank), an IL-1R antagonist, may decrease tumor inflammation and improve outcomes in MBC patients (pts). Methods: Eleven pts HER2– received nab paclitaxel (n = 3), eribulin 5) or capecitabine 2) along Ank daily following 2 week treatment only. One pt had progressive prior to chemotherapy for 14 days. Blood was collected treatment, then at weeks, monthly 6 months (mos). 11...
1068 Background: TNBC are mostly “basal-like” tumors, that have been shown to overexpress Secreted Protein Acidic and Rich in Cysteine (SPARC). Endothelial transcytosis of nab-P via albumin- gp60 -cav1 binding albumin SPARC results high intratumoral levels nab-P. Exploiting this the dysfunctional DNA repair basal we hypothesized + C would produce rates pCR TNBC, further enhanced by antiangiogenesis properties B. Methods: Eligible women had operable ≥ 2 cm. breast nodes were primary &...
TPS1110 Background: The internalizable transmembrane glycoprotein NMB (gpNMB) is overexpressed in 20% of BC, including 40% TNBC (Yardley JCO, press), where it a poor prognostic marker (Rose CCR 2010). gpNMB enhances tumor invasion and metastasis promotes angiogenesis preclinical models. GV novel antibody drug conjugate targeting the potent cytotoxin monomethylauristatin E (MMAE) to gpNMB+ cells. In Phase I/II study (Bendell 2014) II "EMERGE" demonstrated promising activity, particularly pts...
Study Objectives. To compare the antiemetic effectiveness and safety of oral granisetron plus dexamethasone with those ondansetron administered before emetogenic chemotherapy. Design. Randomized, prospective, multicenter, open‐label study. Settings. University‐teaching hospital veterans health care system. Patients. Sixty‐one chemotherapy‐naïve patients scheduled to receive antineoplastic agents. Intervention. A single‐dose 1 mg 12 or 16 was Measurements Results. Twenty‐four hours after...
Abstract BACKGROUND: UFT, a combination of uracil and ftorafur, was developed to combine the cytotoxic effects 5‐fluorouracil (5‐FU) with convenient oral dosing. Leucovorin is combined UFT further potentiate effect 5‐FU on tumor cells. Orally administered leucovorin provide higher peak plasma concentrations prolonged therapeutic compared continuous infusion 5‐FU. METHODS: Ninety‐four patients metastatic breast cancer who had been previously treated anthracyclines and/or taxanes were...
553 Background: The phase 3 BOLERO-2 study at 18 months’ median follow-up showed that everolimus (EVE) + exemestane (EXE) significantly improved progression-free survival (PFS) vs EXE alone in 724 hormone-receptor–positive (HR ) advanced breast cancer (ABC) patients with recurrence/progression during/after nonsteroidal aromatase inhibitor (NSAI) therapy. A higher rate of grade 3/4 adverse events was noted EVE EXE, but not associated deterioration quality life (QOL) based on the EORTC QLQ-C30...
125 Background: BOLERO-2, a phase III study, randomized 724 patients with hormone-receptor–positive metastatic breast cancer, who had recurrence or progression on/after prior nonsteroidal aromatase inhibitor therapy, to everolimus (EVE) + exemestane (EXE) EXE placebo. A preplanned 12-mo median time interim analysis demonstrated that EVE significantly improved progression-free survival (PFS) vs placebo, but resulted in higher rate of grade 3-4 toxicity. Per-protocol reported HRQoL data are...
155 Background: The phase III BOLERO-2 study at 18 months’ median follow-up showed that everolimus (EVE) + exemestane (EXE) significantly improved progression-free survival (PFS) vs EXE alone in 724 patients with hormone receptor–positive (HR+) advanced breast cancer (ABC) recurrence/progression during/after nonsteroidal aromatase inhibitor (NSAI) therapy. A higher rate of grade 3/4 adverse events was noted EVE but not associated deterioration quality life (QOL) based on the EORTC QLQ-C30...
Abstract Background: Androgen Receptor (AR) signaling is a new target present in and under evaluation all breast cancer subtypes. AR expression noted 70%-90% of primary tumors, up to 75% metastases associated with resistance endocrine therapy. Orteronel, an oral, selective, nonsteroidal inhibitor androgen synthesis, being developed as therapy for hormone-sensitive cancers. In preclinical studies, orteronel suppresses sex hormone levels blood hormone-dependent malignant tissue. This study...